Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Maraviroc.

Hind Fadel1, Zelalem Temesgen

  • 1Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Drugs of Today (Barcelona, Spain : 1998)
|January 5, 2008
PubMed
Summary
This summary is machine-generated.

Maraviroc, a new CCR5 antagonist, is approved for treatment-experienced adults with CCR5-tropic HIV-1. It shows superior virologic and immunologic outcomes compared to optimized background therapy alone.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Calcium Intake and Bone Mineral Density in People With HIV and/or Chronic Hepatitis C.

Open forum infectious diseases·2025
Same author

Operational considerations of select new treatment recommendations for drug-susceptible and drug-resistant tuberculosis.

Journal of clinical tuberculosis and other mycobacterial diseases·2025
Same author

Blasto-ing through the chest wall: Empyema necessitans due to pulmonary blastomycosis.

IDCases·2025
Same author

HIV Pre-Exposure Prophylaxis: New and Upcoming Drugs to Address the HIV Epidemic.

Drugs·2023
Same author

Trimethoprim-sulfamethoxazole significantly reduces the risk of nocardiosis in solid organ transplant recipients: systematic review and individual patient data meta-analysis.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2023
Same author

Pulmonary tuberculosis complicated by pneumothorax, and acute respiratory distress syndrome (ARDS) in the settings of advanced HIV disease: A case report.

Journal of clinical tuberculosis and other mycobacterial diseases·2023
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Virology

Background:

  • Maraviroc represents a novel CCR5 antagonist class for antiretroviral therapy.
  • Approved for adult patients with CCR5-tropic HIV-1 resistant to other agents.

Purpose of the Study:

  • To evaluate the efficacy and safety of Maraviroc in treatment-experienced HIV-1 patients.
  • To assess Maraviroc's effectiveness against CCR5-tropic HIV-1 strains.

Main Methods:

  • Two pivotal Phase III studies (MOTIVATE-1 and -2) were conducted.
  • Maraviroc was administered in combination with optimized background therapy (OBT).
  • Outcomes were compared against OBT alone in patients with CCR5-tropic HIV-1.

Main Results:

Related Experiment Videos

  • Maraviroc plus OBT demonstrated superior virologic and immunologic outcomes compared to OBT alone.
  • In vitro activity was confirmed against diverse CCR5-tropic isolates, including multi-drug resistant strains.
  • Maraviroc exhibited acceptable safety and tolerability, with adverse events comparable to placebo.

Conclusions:

  • Maraviroc is an effective treatment option for treatment-experienced adults with CCR5-tropic HIV-1.
  • The drug offers a new therapeutic strategy for patients with multi-drug resistant HIV-1.
  • Maraviroc provides a favorable safety profile in combination therapy.